Andrew Brenner, MD
Enriched profileProfessor of Medicine, Division of Hematology and Oncology, UT Health San Antonio; Neuro-Oncology Program Leader and Breast Medical Oncologist, Mays Cancer Center (UT Health San Antonio MD Anderson Cancer Center) · UT Health San Antonio
Andrew Brenner is Professor of Medicine, Division of Hematology and Oncology, UT Health San Antonio; Neuro-Oncology Program Leader and Breast Medical Oncologist, Mays Cancer Center (UT Health San Antonio MD Anderson Cancer Center) at UT Health San Antonio. OpenAlex indexes 520 publications with 9,184 citations (h-index 47); ClinicalTrials.gov lists 15 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Andrew Brenner, MD, PHD, is Professor of Medicine, Division of Hematology and Oncology, UT Health San Antonio. The public record shows 520 publications with 9,184 citations (h-index 47), centered on Glioma Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism, Advanced Breast Cancer Therapies. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 11 companies, 6 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2025 · Nature communications
- Top research focus: Glioma Diagnosis and Treatment
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 122.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
Sponsor: The University of Texas Health Science Center at San Antonio
- Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Sponsor: Plus Therapeutics
- DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Sponsor: Diakonos Oncology Corporation
Industry payments
Updated 15 Oct 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- PFIZER INC.Program year202423 payments$41,066openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
40.5%Other antiepileptics12.9%Levetiracetam75%Levetiracetam Er26%Part D<11 patientsFatty acid derivatives8.8%Divalproex Sodium Er59%Divalproex Sodium41%Part D<11 patients+ 4 more classes in this area
Cancer & immunology
32.8%Aromatase Inhibitor27.3%Letrozole65%Anastrozole24%Exemestane11%Part D<11 patientsEstrogen Agonist/Antagonist5.5%Tamoxifen Citrate100%Part D<11 patientsMetabolism & gastrointestinal
17.4%Serotonin-3 Receptor Antagonist10.7%Ondansetron Hcl100%Part D≥21 patientsProton pump inhibitor6.6%Esomeprazole Magnesium54%Omeprazole46%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
6 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
University of Texas Hlth Science Center
FY2026$479,512R01CA269866 - Mays Cancer Center at UT San Antonio Health Science Center
University of Texas Hlth Science Center
FY2026$131,008P30CA054174 - Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
University of Texas Hlth Science Center
FY2025$530,240R01CA269866
Congress activity
Updated 15 Oct 2026
97 congress contributions (2010–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 3492: Targeting ALKBH5 mediated ChREBP signaling impairs cancer stem cell metabolism and tumor growth in medulloblastoma
AACR Annual Meeting
AACR2026Co-author - Abstract 461: Next-generation ERβ agonists with superior brain uptake suppress glioblastoma and enhance temozolomide response.
AACR Annual Meeting
AACR2026Co-author - Abstract 2620: m6A demethylase ALKBH5 regulates medulloblastoma growth and progression
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Convection enhanced delivery of Rhenium ((186)Re) Obisbemeda ((186)RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial.
Nature communications
Clinical Trial2025 - Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U.
JCO precision oncology
Clinical Trial2024 - Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.
Clinical cancer research
Article2023 - Preclinical Development of Brain Permeable ERβ Agonist for the Treatment of Glioblastoma.
Molecular cancer therapeutics
Article2023 - Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma.
Clinical cancer research
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/profile/Andrew-Brenner
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
m.facebook.com/UTHealthsaMDAnderson/photos/a.357498222759/10159217970097760
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →m.facebook.com ↗ - Other
plustherapeutics.com
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →plustherapeutics.com ↗ - Other
respect-trials.com/andrew-brenner
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →respect-trials.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →directory.uthscsa.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →directory.uthscsa.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →directory.uthscsa.edu ↗
- Board Certified
American Board of Internal Medicine – Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Board Certified
United Council for Neurologic Subspecialties – Neuro-Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗
Editorial & leadership roles
journal and society appointments- Co-Leader
Experimental and Developmental Therapeutics Program, Mays Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Neuro-Oncology Program Leader
Mays Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →respect-trials.com ↗ - Clinical Investigator
Institute for Drug Development, UT Health San Antonio
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tpr.org ↗
Secondary affiliations
appointments beyond the home institution- Clinical Investigator
Institute for Drug Development, UT Health San Antonio
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.uthscsa.edu ↗ - Scientific Advisory Board member; joined Plus Therapeutics
Inc. management team (biotech developing radiotherapeutics for glioblastoma)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →globenewswire.com ↗
Media & interviews
press, podcasts and appearances- TPR (Texas Public Radio) 'Petrie Dish' segment
'Science & Medicine: A breakthrough for glioblastoma patients that may lengthen lives' (Dec 2025) …
2025 - KSAT 12 'The Conversation' TV segment
'Mays Cancer Center recruiting glioblastoma patients for trial' (Aug 2025), Brenner interviewed as lead investigator of the RESPECT-GBM trial
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ksat.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Ralph Defronzo, MD
UT Health San Antonio
Virginia Kaklamani, MD
UT Health San Antonio
Allen Anderson, MD
UT Health San Antonio
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
David Reardon, MD
Dana-Farber Cancer Institute